Ulo Palm - Mar 15, 2022 Form 4 Insider Report for Vaxxinity, Inc. (VAXX)

Role
Chief Medical Officer
Signature
Rene Paula Molina, attorney-in-fact for Ulo Palm
Stock symbol
VAXX
Transactions as of
Mar 15, 2022
Transactions value $
$0
Form type
4
Date filed
3/15/2022, 08:56 PM
Previous filing
Nov 15, 2021
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VAXX Class A common stock 450 Mar 15, 2022 Held by spouse F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VAXX Restricted Stock Units Award $0 +100K $0.00 100K Mar 15, 2022 Class A common stock 100K Direct F2, F3
holding VAXX Stock Option (right to buy) 233K Mar 15, 2022 Class A common stock 233K $13.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held by Kathrin Palm, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kathrin Palm in which the Reporting Person has no pecuniary interest.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A common stock.
F3 The Reporting Person received restricted stock units subject to a four-year vesting schedule, vesting 100% on March 15, 2026, subject to the Reporting Person's continued employment with the Issuer through the vesting date. The restricted stock units do not expire but are settled in shares of Class A common stock as soon as practicable after the vesting date.
F4 These options are subject to a four-year time-vesting schedule, with 25% vesting on November 11, 2022 and the remainder vesting in equal installments each month during the remainder of the vesting schedule, subject to the Reporting Person's continued employment with the Issuer through the vesting date.